PGNY logo

Progyny, Inc. Stock Price

NasdaqGS:PGNY Community·US$2.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 48 Fair Values set on narratives written by author

PGNY Share Price Performance

US$31.19
7.99 (34.44%)
US$34.92
Fair Value
US$31.19
7.99 (34.44%)
10.7% undervalued intrinsic discount
US$34.92
Fair Value
Price US$31.19
AnalystHighTarget US$34.92
AnalystConsensusTarget US$29.73
AnalystLowTarget US$26.43

PGNY Community Narratives

·
Fair Value US$34.92 10.7% undervalued intrinsic discount

Delayed Parenthood And Healthcare Consumerism Will Boost Fertility Ecosystem

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$29.73 4.9% overvalued intrinsic discount

Rising Demand For Women's Health Will Transform Market Opportunity

0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
·
Fair Value US$26.43 18.0% overvalued intrinsic discount

Tightening US Healthcare Policies And Gig Shifts Will Dampen Prospects

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$26.43
18.0% overvalued intrinsic discount
Revenue
6.29% p.a.
Profit Margin
9.23%
Future PE
14.27x
Price in 2029
US$32.47

Trending Discussion

No trending discussion available.

Updated Narratives

PGNY logo

PGNY: Measured Fair Value View As Fertility Utilization And Guidance Shape Outlook

Fair Value: US$34.92 10.7% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
PGNY logo

PGNY: Conservative Guidance And Share Repurchases Will Support Future Stock Upside

Fair Value: US$29.73 4.9% overvalued intrinsic discount
24 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
PGNY logo

PGNY: Healthy Utilization And Client Transition Progress Will Support Future Policy Tailwinds

Fair Value: US$26.43 18.0% overvalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with proven track record.

0 Risks
3 Rewards

Progyny, Inc. Key Details

US$1.3b

Revenue

US$981.4m

Cost of Revenue

US$311.8m

Gross Profit

US$244.1m

Other Expenses

US$67.7m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 06, 2026
0.86
24.11%
5.23%
0%
View Full Analysis

About PGNY

Founded
2008
Employees
846
CEO
Peter Anevski
WebsiteView website
www.progyny.com

Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.